
Wellgistics Health, Inc.
93
Recent news coverage includes sector and market updates but lacks direct company-specific developments for Wellgistics Health, Inc.
- Soybeans posted gains following export announcements, reflecting commodity market movements relevant to agricultural sectors [N1].
- Soybeans prices increased on Friday after export announcements, indicating market responsiveness to trade developments [N2].
- Tariffs have pushed prices up, with retail and industrial investors advised not to expect a quick reversal, highlighting macroeconomic factors affecting markets [N3].
- Arrive AI provided three key takeaways for long-term investors, illustrating ongoing interest in AI sector developments [N4].
- Novo Nordisk secured EU approval for FREHEMGO in Haemophilia A, demonstrating regulatory progress in biopharma [N5].
- COSCIENS Biopharma reported a widened Q3 loss, indicating challenges in the biopharma sector [N6].
- Alphamin Resources Corp. reported a profit climb in Q3, reflecting positive mining sector performance [N7].
- Bragg Gaming Group Inc. reported a rise in Q3 loss, showing volatility in gaming sector financials [N8].
Wellgistics Health, Inc. operates in the healthcare sector with a focus on pharmaceutical supply chain and digital health solutions. The company’s leadership team brings expertise in pharmacy, clinical care, and healthcare technology. It is publicly traded on NASDAQ under the ticker WGRX. The company has filed recent SEC reports including an amended annual report for 2025 and a quarterly report for Q3 2026, providing financial and governance disclosures. The company’s financial snapshot as of September 30, 2026, shows positive net income but liquidity ratios below 1, indicating current liabilities exceed current assets.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Wellgistics Health, Inc. is a publicly traded company on NASDAQ (ticker: WGRX) with detailed disclosures in its 10-K/A and 10-Q filings through 2026. The company’s leadership team includes experienced executives in pharmacy and healthcare technology. The latest financial snapshot as of September 30, 2026, shows net income of approximately $10.6 million and liquidity ratios indicating limited short-term liquidity relative to current liabilities.
Wellgistics Health benefits from a leadership team with strong backgrounds in pharmacy and healthcare technology, which supports its strategic focus on pharmaceutical supply chain transparency and digital health solutions. The company reported positive net income in the latest quarter, indicating operational profitability. Its executive team’s experience in pharmacy benefit management and digital health innovation could enable the company to develop differentiated offerings in a complex healthcare market.
The company’s liquidity ratios as of September 30, 2026, indicate limited short-term liquidity, with current liabilities significantly exceeding current assets. This could pose challenges for meeting near-term obligations. The absence of detailed revenue or segment disclosures limits visibility into business diversification and growth drivers. Additionally, the company’s recent filings note ongoing liquidity needs as a risk factor. Lack of recent company-specific news coverage may also reflect limited market visibility or investor engagement.
The company’s moat appears to be based on its specialized expertise in pharmaceutical supply chain management and digital health innovation, supported by a leadership team with deep industry experience. The presence of experienced executives with backgrounds in pharmacy benefit management and clinical pharmacy may provide competitive advantages in developing patient-centric healthcare solutions. However, detailed information on proprietary technology, patents, or exclusive partnerships is not disclosed in the available filings.
• Liquidity Risk: The company’s current ratio of 0.14 and cash ratio of 0.01 as of September 30, 2026, indicate limited liquidity to cover short-term liabilities, posing potential financial risk.
• Limited Business Disclosure: There is limited public disclosure on the company’s revenue streams, product offerings, or market segments, reducing transparency on business model robustness.
• Ongoing Liquidity Needs: The latest 10-Q filing notes ongoing liquidity needs as a material risk factor, which could impact operational stability.
Business trends: The company focuses on pharmaceutical supply chain transparency and digital health innovation supported by experienced leadership.
Execution milestones: Recent SEC filings provide updated financial and governance disclosures; leadership appointments reinforce strategic direction.
Key risks: Limited short-term liquidity and ongoing liquidity needs pose financial risks; lack of detailed revenue and segment disclosures reduces business model transparency.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Wellgistics Health, Inc. is a U.S.-based company with principal executive offices in Tampa, Florida.
- The company is publicly traded on NASDAQ under the ticker WGRX.
- As of March 6, 2026, the company had approximately 105.85 million shares issued and outstanding.
- The company’s leadership includes President Prashant Patel (appointed October 3, 2025), Interim CFO Eric Sherb (appointed October 7, 2025), Chief Clinical Officer Dr. Shafaat Pirani (joined February 2023), Chief Information Officer Srini Kalla, and Chairman of the Board Suren Ajjarapu.
- The Board includes independent directors Donald Fell, Gary Herman, and Marlene Velez.
- The company filed an amended 10-K for fiscal year ended December 31, 2025, on April 24, 2026, and a 10-Q for the quarter ended September 30, 2026, on November 13, 2026.
- Financial snapshot as of 2026-09-30 shows cash and equivalents of $476,598, current assets of $5,220,035, and current liabilities of $36,549,784, resulting in a current ratio of 0.14 and a cash ratio of 0.01.
- Net income for the quarter ended 2026-09-30 was $10,589,764 with basic EPS of $3.29 and diluted EPS of $2.72.
- The company’s liquidity ratios indicate limited short-term liquidity relative to current liabilities as of the latest quarter.
- The company’s executive leadership has backgrounds in pharmacy, healthcare technology, and financial consulting, with experience in pharmaceutical supply chain, digital health, and pharmacy benefit management.
- No material changes in risk factors were reported in the latest 10-Q except ongoing liquidity needs.
- Recent news coverage includes general market and sector news but no direct company-specific news was identified in the provided recent news business items.
Generated 2026-11-14
- S1 | 2026-04-24 | 10-K/A
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-11-14 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
- N2 | 2026-11-14 | www.nasdaq.com | Soybeans Popping Higher on Friday Following Export Announcements | https://www.nasdaq.com/articles/soybeans-popping-higher-friday-following-export-announcements
- N3 | 2026-11-14 | www.nasdaq.com | Tariffs Pushed Prices Up. Why Retail and Industrial Investors Shouldn't Expect a Quick Reversal | https://www.nasdaq.com/articles/tariffs-pushed-prices-why-retail-and-industrial-investors-shouldnt-expect-quick-reversal
- N4 | 2026-11-14 | www.nasdaq.com | Arrive AI: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/arrive-ai-3-key-takeaways-long-term-investors
- N5 | 2026-11-14 | www.nasdaq.com | Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A | https://www.nasdaq.com/articles/novo-nordisk-secures-eu-approval-frehemgo-haemophilia
- N6 | 2026-11-14 | www.nasdaq.com | COSCIENS Biopharma Inc. Q3 Loss Widens | https://www.nasdaq.com/articles/cosciens-biopharma-inc-q3-loss-widens
- N7 | 2026-11-14 | www.nasdaq.com | Alphamin Resources Corp. Profit Climbs In Q3 | https://www.nasdaq.com/articles/alphamin-resources-corp-profit-climbs-q3
- N8 | 2026-11-14 | www.nasdaq.com | Bragg Gaming Group Inc. Q3 Loss Rises | https://www.nasdaq.com/articles/bragg-gaming-group-inc-q3-loss-rises
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


